This approach highlights the potential of chitosan as a component of drug delivery systems for regulated and prolonged CMN release, although further studies are needed to assess its pharmacokinetics and bioavailability in vivo. Thus, the findings provide credence to the need for further evaluations of FTN risks through dose-response studies and the identification of therapeutic targets for CML-CNP clinical treatment. Here, CNP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.